- Structural heart devices are vital tools used in treating a range of heart defects, including aortic stenosis, mitral regurgitation, and atrial septal defects, by supporting or replacing damaged heart structures through minimally invasive or surgical interventions
- The demand for these devices is being significantly driven by the increasing prevalence of structural heart diseases, especially among the elderly population, alongside rising incidences of congenital heart defects in new-borns
- North America stands out as the dominant region in the structural heart devices market due to its highly developed healthcare infrastructure, widespread adoption of cutting-edge cardiac technologies, and strong presence of key medical device manufacturers
- For instance, the U.S. has seen a rapid increase in the adoption of transcatheter aortic valve replacement (TAVR) procedures, supported by favourable reimbursement policies and ongoing clinical trials demonstrating long-term efficacy and safety
- Globally, structural heart devices are considered one of the most transformative innovations in the cardiovascular field, second only to traditional stent-based interventions, due to their role in improving survival rates and quality of life for patients with complex cardiac conditions
